Loading...
Loading...
PRLD| Name | Value |
|---|---|
| Revenues | 3.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 3.0M |
| Operating Expense | 37.4M |
| Operating I/L | -34.4M |
| Other Income/Expense | 2.1M |
| Interest Income | 0.0M |
| Pretax | -32.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -32.3M |
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company specializing in the discovery and development of novel precision cancer medicines. The company's primary focus is on developing PRT543 and PRT811, both in Phase 1 clinical trials for various solid tumors and myeloid malignancies. Additionally, Prelude Therapeutics is working on several other promising compounds, including PRT1419, PRT2527, PRT-SCA2, PRT3645, and PRT-K4, targeting different cancer types. These innovative therapies are designed to address unmet medical needs and have the potential to generate revenue through successful clinical development and commercialization.
